Eli Lilly and Company (LLY) Stock Price Prediction
AI-generated price target with bull & bear cases · Re-evaluated every trading morning and evening
Our AI model’s current price target for LLY is $1,299.72 — 8.2% above the latest price of $1201.42.
Target vs 52-Week Range
Bull Case vs Bear Case
Bull Case
The bullish outlook for Eli Lilly is primarily driven by its sustained leadership in the burgeoning GLP-1 market with Mounjaro and Zepbound, which are highly effective treatments. The recent approval and market launch of orforglipron (Foundayo), the first oral GLP-1, is anticipated to unlock a multi-billion dollar revenue stream by expanding the total addressable market beyond injectable options. Further upside is expected from its extensive and diversified pipeline, particularly the triple incretin agonist retatrutide, which has demonstrated positive Phase 3 results for both type 2 diabetes and obesity and could establish new efficacy benchmarks. Ongoing efforts to scale up manufacturing capacity are aimed at meeting unmet demand and have the potential to deliver revenue surprises beyond current supply-constrained projections. Strategic acquisitions, such as 4E Therapeutics for non-opioid pain treatment and Centessa Pharmaceuticals for sleep-wake disorders, contribute to portfolio diversification and reduce reliance solely on GLP-1 products. The company's strong financial performance, characterized by accelerating revenue growth and high operating margins, is expected to support continuous earnings growth.
Bear Case
The primary risks for Eli Lilly stem from intense and structural pressure on drug pricing from governmental bodies and pharmacy benefit managers (PBMs), especially for high-volume GLP-1 drugs, which could lead to significant rebates and impact profit margins. The emergence of new competitors in the GLP-1 arena, potentially offering more effective, less expensive, or more conveniently administered products, poses a substantial threat to Lilly's market dominance. Despite ongoing investments, manufacturing and supply chain constraints could persist due to overwhelming demand, potentially leading to product shortages. The stock's premium valuation, reflected in its high P/E ratio, makes it susceptible to changes in interest rate expectations and any deceleration in growth or pipeline setbacks. Regulatory risks, including evolving oversight from bodies like the FDA and EMA, cybersecurity threats, and the complexities of international operations, present continuous challenges. Additionally, initial launch data for Foundayo was underwhelming, raising questions about the demand trajectory for the oral drug despite adequate supply. Eli Lilly has also issued warnings regarding the safety concerns associated with compounded tirzepatide mixed with vitamin B12.
Model-assessed risk level: Medium
Key Catalysts to Watch
Continued approval and market uptake of orforglipron (Foundayo), the oral GLP-1 drug.
Further positive clinical data readouts and potential regulatory approvals for retatrutide, the triple incretin agonist, across various indications.
Successful expansion and de-bottlenecking of manufacturing capacity to meet the surging demand for GLP-1 drugs.
Data readouts from competitors in the GLP-1 space at major scientific conferences, such as the American Diabetes Association Scientific Sessions.
New drug approvals and pipeline advancements in therapeutic areas like oncology, immunology, and neuroscience, diversifying revenue streams beyond GLP-1s.
The upcoming Q2 2026 Earnings Report (expected August 5, 2026), which will provide crucial updates on demand, pricing, and pipeline progress.
The impact of the Medicare GLP-1 Bridge program, expanding access to obesity medicines for eligible Medicare Part D patients starting July 1, 2026.
Technical Backdrop
RSI-14
72.2
50-Day MA
$1012.91
200-Day MA
$904.69
From 52-Wk High
-1.4%
Full momentum breakdown: Is LLY overbought or oversold?
Model Notes
Eli Lilly and Company (LLY) is a prominent global pharmaceutical company with a strong focus on cardiometabolic health, oncology, immunology, and neuroscience. Its recent substantial growth has been propelled by blockbuster GLP-1 drugs like Mounjaro and Zepbound, used for diabetes and obesity. The company reported robust Q1 2026 financial results, achieving 56% revenue growth and subsequently increasing its full-year guidance. Eli Lilly boasts a resilient pipeline with significant advancements, including the U.S. approval of orforglipron (Foundayo) in April 2026, marking it as the first oral GLP-1 receptor agonist for obesity, and positive Phase 3 results for retatrutide, a triple incretin agonist, which is anticipated to solidify its leadership in the incretin market for the coming decade. The company is actively diversifying its portfolio through strategic acquisitions, such as 4E Therapeutics for non-opioid pain treatment in June 2026, and a recent acquisition to advance treatments for sleep-wake disorders. Eli Lilly continues to heavily invest in research and development and expand its manufacturing capabilities to meet the high demand for its rapidly growing product lines.
Eli Lilly's stock (LLY) exhibits a strong bullish trend with significant upward momentum. The 50-day moving average, currently around $1,106.90, is positioned above its 200-day moving average of $1,023.90, indicating a bullish 'golden cross' formation. The stock is trading consistently above its 5, 20, 50, and 200-day exponential moving averages, signaling a robust bullish trend. The 14-day Relative Strength Index (RSI) is approximately 68.5, residing in neutral territory but nearing overbought conditions. The Moving Average Convergence Divergence (MACD) indicator also provides a bullish 'Buy' signal. Key support levels are identified around $849.75, with resistance around $1,229.93.
Current Street Context
July 6, 2026The AI price target for Eli Lilly and Company is $1,299.72. The company's next earnings release is anticipated on August 6, 2026. For the second quarter of 2026, analysts are projecting an EPS of $8.98, representing a significant year-over-year increase of 42.31%. Recent analyst sentiment is highly positive, with Cantor Fitzgerald raising its price target to $1,350 from $1,230 and maintaining an 'Overweight' rating, citing expectations of strong Q2 results and potential top-line guidance raises. RBC Capital has also reiterated an 'Outperform' rating with a $1,250 price target. The consensus analyst price target stands at $1,239.52, with a high forecast of $1,400.00. The AI price target aligns with this optimistic outlook, suggesting continued upside potential.
Frequently Asked Questions
What is the price target for LLY?
How is this forecast generated?
How accurate are stock price predictions?
Will LLY stock go up?
How often does the AI target change?
Methodology
The price target, bull and bear cases, and risk level are produced by an AI model that reviews LLY’s fundamentals, technical posture, current news flow, and analyst commentary via live web search. It re-evaluates every trading morning and evening; the street-context commentary refreshes each trading evening.
Targets are estimates, not guarantees. No model reliably predicts short-term prices — treat this page as a structured summary of what current information might justify, alongside the risks that could break the thesis.
Not Financial Advice
This page is for education and information only. Indicators are mechanical calculations, AI commentary can contain errors, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a qualified financial advisor. See our full disclaimer.
Keep Digging on LLY
Eli Lilly and Company Overview
Price, chart, analysis & financials
LLY: Overbought or Oversold?
Updated daily
LLY: Why Is It Moving?
Updated daily
LLY: Undervalued or Overvalued?
Updated daily
Same question, Healthcare peers